Intrepid Labs
- Company typePrivate
- Founded2023
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Intrepid Labs firmographics
Firmographics- Name
- Intrepid Labs
- Legal name
- Intrepid Labs Inc.
- Website
- https://intrepidlabs.tech
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Intrepid Labs industry classification
Industry- Product category
- AI-Driven Drug Formulation Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD), Lab Analytics, Utilization Management & Operational Intelligence (HLACAMAK)
Keywords
Where Intrepid Labs is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Intrepid Labs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing and Technology Services: Multi-year strategic partnerships providing access to Intrepid's ML platforms (ANDROMEDA, VALIANT) for pharmaceutical formulation development. Revenue generated through partnership agreements with drug development companies.
- Collaborative Development: Revenue from collaborative development projects with pharmaceutical partners, combining Intrepid's AI/ML capabilities with partner platforms. Pilot projects followed by wider rollout across formulation development workflows.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Intrepid Labs product offering
Product offeringCore offering
Intrepid Labs builds and licenses AI- and robotics-powered platforms (VALIANT and ANDROMEDA) that automate drug formulation development. The closed-loop system uses active machine learning to plan, prepare, and characterize formulation candidates in parallel, enabling pharmaceutical and biotech partners to accelerate formulation optimization, reduce API consumption, and shorten pre-clinical timelines.
Product overview
Intrepid Labs offers a proprietary AI and robotics platform for accelerated drug formulation development. The core technology consists of VALIANT, a modular autonomous laboratory platform that uses AI and robotics to optimize drug formulations in parallel, combined with the ANDROMEDA machine learning platform for formulation design and optimization. The company also provides the Intrepid Dashboard for customers to access their formulation data. These products work together to reduce development timelines from months to days by leveraging active learning and robotic automation.
Differentiator
Problem solved
Functional benefit
Brands
- VALIANT: Intrepid's proprietary platform that harnesses AI and robotics to enable accelerated development of fully optimized formulations of drugs. It is a modular, autonomous laboratory that leverages data-driven experiment planning to optimize formulation compositions.
- ANDROMEDA
Products and services
- VALIANT VALIANT is a modular, autonomous laboratory platform that combines active machine learning with advanced robotics to plan, prepare, and characterize drug formulation candidates in parallel. It is targeted at pharmaceutical and biotech companies seeking to accelerate formulation optimization and reduce development timelines and API consumption across diverse formulation types including injectable depots, solid dosage forms, and nanoparticles.
- ANDROMEDA ANDROMEDA is a machine learning platform for formulating and optimizing clinical drug products. It uses active learning to rapidly explore formulation options, reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making. It is deployed via a secure independent AI instance per project to ensure data protection, and was commercialized through the multi-year strategic partnership with Quotient Sciences.
Quantifiable outcome
- Reduces drug formulation development time by up to 50%
- +4 more outcomes
Companies that use Intrepid Labs
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Intrepid Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Intrepid Labs partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and supporting.
- Quotient SciencesflagshipMulti-year strategic partnership to advance AI in early drug development. Combines Quotient's Translational Pharmaceutics platform with Intrepid's ANDROMEDA ML platform. After two years of collaboration, companies report they can save up to 50% of formulation development time and achieve comparable reductions in API usage. Initial pilot projects comparing traditional and AI-assisted methods will begin immediately, with plans for wider rollout following evaluation. A secure independent AI instance is deployed for each project to ensure data protection. This partnership culminated in the first reported AI-designed formulation entering Phase I clinical evaluation.
- Johnson & Johnson Innovation - JLABScoreIntrepid Labs is a JLABS resident company, providing access to JLABS' startup ecosystem, resources, and network within the pharmaceutical and biotech industry.
- Vector InstitutecoreMember of the Vector Institute's Fast-Lane Program, providing access to Canada's leading AI research institute and talent network. Prof. Alán Aspuru-Guzik holds a CIFAR AI Chair at the Vector Institute.
- University of TorontocoreDeep research partnership through the Acceleration Consortium, a strategic initiative at UofT that received a $200M grant in 2023 from the Canada First Research Excellence Fund. Multiple co-founders are professors at UofT. Co-founder Prof. Alán Aspuru-Guzik is Canada 150 Research Chair in Theoretical Chemistry at UofT.
- Mila Quebec AI InstitutesupportingPartnership with Mila (Quebec Artificial Intelligence Institute) providing access to additional AI research expertise and collaboration opportunities.
- MaRS Discovery DistrictsupportingPartnership with MaRS Discovery District, Toronto's innovation hub. Intrepid Labs' headquarters is located at MaRS Centre.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Intrepid Labs competitors and assessment
Company assessmentDirect peers
- Kebotix: Co-founded by Alán Aspuru-Guzik, Kebotix applies AI and robotics to chemistry and materials discovery — closely overlapping Intrepid's active-learning-plus-automation formulation approach.
- XtalPi: AI-driven drug discovery and crystal/prediction platform combining computation with robotic experimentation, targeting pharma R&D efficiency — directly comparable to Intrepid's VALIANT/ANDROMEDA stack.
Broad incumbents
- Schrödinger: Established computational chemistry and predictive modeling platform serving large pharma across discovery and development, providing broader but overlapping capabilities vs. Intrepid's focused formulation play.
- Recursion Pharmaceuticals: Public, well-capitalized AI-driven drug discovery company combining high-throughput biology with ML — addresses the broader drug development funnel that Intrepid targets via formulation.
- Isomorphic Labs: Alphabet/DeepMind-backed computational drug design company using AI across the full drug development pipeline; broad incumbent in AI pharma R&D.
Emerging players
- Insitro: ML-driven drug discovery company combining high-throughput data generation with predictive models; targets similar pharma enterprise buyers as Intrepid though focused earlier in discovery.
- Iambic: AI-driven drug discovery company using physics-informed ML for small molecule design; competing for the same enterprise AI-pharma partnerships.
- Genesis Therapeutics: AI-first biotech combining graph neural networks and lab-in-the-loop experimentation to accelerate small molecule discovery — overlapping lab-automation-and-ML paradigm with Intrepid.
- Cradle: AI platform for protein and biologics engineering with iterative wet-lab feedback, applying ML-plus-lab automation similar in spirit to Intrepid's formulation platform.
Others
- Benchling: Cloud lab informatics platform (LIMS/ELN) widely used by pharma R&D — adjacent enabling technology rather than a direct competitor, but increasingly overlapping in AI-for-formulation workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Intrepid Labs social profiles
Digital presenceIntrepid Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intrepid Labs leadership team
Management profileNumber of profiles
Profiles9 records
Intrepid Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intrepid Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intrepid Labs
What does Intrepid Labs do?
Intrepid Labs builds and licenses AI- and robotics-powered platforms (VALIANT and ANDROMEDA) that automate drug formulation development. The closed-loop system uses active machine learning to plan, prepare, and characterize formulation candidates in parallel, enabling pharmaceutical and biotech partners to accelerate formulation optimization, reduce API consumption, and shorten pre-clinical timelines.
Is Intrepid Labs a public or private company?
Intrepid Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Intrepid Labs founded?
Intrepid Labs was founded in 2023. It employs 11 to 50 people.
Where is Intrepid Labs based?
Intrepid Labs is headquartered in Toronto, Canada, in the North America region.
How does Intrepid Labs make money?
Two revenue lines are on record. Platform Licensing and Technology Services are the primary driver. The others are collaborative Development.
Who are Intrepid Labs's main competitors?
Direct peers on record are Kebotix and XtalPi. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Emerging players are Insitro, Iambic, Genesis Therapeutics and Cradle. Benchling is listed as an others.
Does Intrepid Labs have an API?
No public API is recorded for Intrepid Labs.
What industry is Intrepid Labs in?
Intrepid Labs's product category is AI-Driven Drug Formulation Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAG, Lab Automation, Instrument Control & Workflow Orchestration Software. Its NAICS code is 541714 and its SIC code is 3826.